HEC585 not checked
Sunshine Lake Pharma Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage”In the company’s words, NCT05139719 on ClinicalTrials.gov
- Tested for
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
- Main trialPhase 3
- “A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)”In the company’s words, NCT07082842 on ClinicalTrials.gov
Other drugs for Idiopathic Pulmonary Fibrosis (IPF)
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up2
- DecPhase 2 trial completes · ClinicalTrials.gov
- 15 Jan 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 15 Jan 2031 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | |
| Phase 2Active, not recruiting | 16 Jul 2025 | Phase ll Study of HEC585 in Patients With IPF | |
| Phase 2Recruiting | Dec 2026 | A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients | |
| Phase 1Completed | 23 Aug 2021 | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects | |
| Phase 1Completed | 30 Nov 2021 | Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects | |
| Phase 1Completed | 30 Nov 2021 | To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers | |
| Phase 1Completed | 14 Aug 2022 | Study on the Body Mass Balance and Biotransformation of [14C]-HEC585 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026